when we discuss revenues , we may , at times , refer to revenues summarized differently than the regulation s-x requirements . the terminology , definitions , and applications of terms that we use to describe revenues may be different from terms used by other companies . we use the following terms to describe revenues : revenues – our revenues are presented net of sales returns and allowances . product revenues – we define product revenues as revenues generated from sales of consumable and capital equipment products . service revenues – we define service revenues as revenues generated from parts and labor associated with the maintenance , repair , and installation of our capital equipment . service revenues also include hospital sterilization services , instrument and scope repairs , and linen management as well as revenues generated from contract sterilization and laboratory services offered through our applied sterilization technologies segment . capital equipment revenues – we define capital equipment revenues as revenues generated from sales of capital equipment , which includes steam sterilizers , low temperature liquid chemical sterilant processing systems , including system 1 and 1e , washing systems , vhp ® technology , water stills , and pure steam generators ; surgical lights and tables ; and integrated or . consumable revenues – we define consumable revenues as revenues generated from sales of the consumable family of products , which includes system 1 and 1e consumables , v-pro consumables , gastrointestinal endoscopy accessories , sterility assurance products , skin care products , cleaning consumables , barrier product solutions and surgical instruments . recurring revenues – we define recurring revenues as revenues generated from sales of consumable products and service revenues . general overview and executive summary steris plc is a leading provider of infection prevention and other procedural products and services . our mission is to help our customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe . we offer our customers a unique mix of innovative consumable products , such as detergents , gastrointestinal ( `` gi `` ) endoscopy accessories , barrier product solutions , and other products and services , including : equipment installation and maintenance , microbial reduction of medical devices , instrument and scope repair solutions , laboratory testing services , on-site and off-site reprocessing , and capital equipment products , such as sterilizers and surgical tables , and connectivity solutions such as operating room ( “ or ” ) integration . on march 28 , 2019 , steris plc , a public limited company organized under the laws of england and wales ( “ steris uk ” ) , completed a redomiciliation from the united kingdom to ireland ( the “ redomiciliation ” ) . the redomiciliation was achieved through the insertion of a new irish public limited holding company ( “ steris ireland ” ) on top of steris uk pursuant to a court-approved scheme of arrangement under english law ( the “ scheme ” ) . following the scheme effectiveness , steris uk was re-registered as a private limited company with the name steris limited , and steris emerald ie limited , a company established in ireland and a wholly-owned direct subsidiary of steris ireland , was interposed as the direct parent company of steris uk . we operate and report in four reportable business segments : healthcare products , healthcare specialty services , life sciences , and applied sterilization technologies . we describe our business segments in note 11 to our consolidated financial statements , titled `` business segment information . `` the bulk of our revenues are derived from the healthcare , medical device and pharmaceutical industries . much of the growth in these industries is driven by the aging of the population throughout the world , as an increasing number of individuals are entering their prime healthcare consumption years , and is dependent upon advancement in healthcare delivery , acceptance of new technologies , government policies , and general economic conditions . the pharmaceutical industry has been impacted by increased regulatory scrutiny of cleaning and validation processes , mandating that manufacturers improve their processes . within healthcare , there is increased concern regarding the level of hospital acquired infections around the world ; increased demand for medical procedures , including preventive screenings such as endoscopies and colonoscopies ; and a desire by our customers to operate more efficiently , all which are driving increased demand for many of our products and services . the covid-19 pandemic is resulting in the deferral of certain elective medical procedures , which is negatively impacting the demand for some of our products and services . we completed several tuck in acquisitions and asset purchases in fiscal 2020 and 2019 that expanded our product and service offerings to our customers . 23 during fiscal 2020 , we sold the operations of our healthcare specialty services business that were located in china with annual revenues of approximately $ 5.0 million . we continue to invest in manufacturing in-sourcing projects and lean process improvements for the purpose of improving quality , cost and delivery of our products to our customers . u.s. tax reform . on december 22 , 2017 , the u.s. government enacted comprehensive tax legislation commonly referred to as the tax cuts and jobs act ( the “ tcja ” ) . story_separator_special_tag ( 5 ) covid-19 incremental costs includes the additional costs attributable to covid-19 such as enhanced cleaning protocols , personal protective equipment for our employees , event cancellation fees , and payroll costs associated with our response to covid-19 , net of any government subsidies available . healthcare products revenues increased 6.3 % in fiscal 2020 , as compared to fiscal 2019 , reflecting growth in consumable , service and capital equipment revenues of 9.5 % , 6.1 % and 4.2 % , respectively . the increase reflects organic growth , which was partially offset by unfavorable fluctuations in currencies . at march 31 , 2020 , the healthcare products segment 's backlog amounted to $ 170.1 million , increasing $ 15.6 million , or 10.1 % , as compared to the backlog of $ 154.5 million at march 31 , 2019. healthcare specialty services revenues increased 10.5 % in fiscal 2020 , as compared to fiscal 2019. the increase reflects organic growth , which was partially offset by the divestiture of our healthcare specialty services business in china and unfavorable fluctuations in currencies . life sciences revenues increased 10.1 % in fiscal 2020 , as compared to fiscal 2019 , reflecting growth in consumable , capital equipment and service revenues of 14.9 % , 9.8 % and 3.7 % , respectively . the increase reflects organic growth and favorable pricing , which were partially offset by unfavorable fluctuations in currencies . life sciences backlog at march 31 , 2020 amounted to $ 72.4 million , increasing $ 11.7 million , or 19.3 % , as compared to backlog of $ 60.7 million at march 31 , 2019. applied sterilization technologies revenues increased 13.0 % in fiscal 2020 , as compared to fiscal 2019. the increase reflects organic growth , which was primarily attributable to increased demand from medical device customers , which was partially offset by unfavorable fluctuations in currencies . 29 the healthcare products segment 's operating income increased $ 32.7 million to $ 356.4 million in fiscal year 2020 , as compared to $ 323.7 million in fiscal year 2019. the segment 's operating margins were 25.0 % for fiscal year 2020 and 24.2 % for fiscal year 2019. the increases in the fiscal 2020 period were primarily due to increased volumes and favorable product mix . the healthcare specialty services segment 's operating income was flat at $ 64.2 million in fiscal years 2020 and 2019. the segment 's operating margins were 11.4 % for fiscal year 2020 and 12.6 % for fiscal year 2019. the fiscal 2020 operating margin benefited from increased volumes , which were more than offset by investments being made to add capacity in anticipation of continuing demand . the life sciences business segment 's operating income increased $ 12.0 million to $ 144.1 million in fiscal year 2020 , as compared to $ 132.1 million in fiscal year 2019 , primarily due to increased volumes . the segment 's operating margins were 34.6 % for fiscal year 2020 and 34.9 % for fiscal year 2019. the decline in the fiscal 2020 operating margin was primarily due to unfavorable product mix . the applied sterilization technologies segment 's operating income increased $ 49.1 million to $ 270.9 million in fiscal year 2020 , as compared to $ 221.8 million in fiscal year 2019. the applied sterilization technologies segment 's operating margins were 43.2 % for fiscal year 2020 and 40.0 % for fiscal year 2019. the increases in the fiscal 2020 period were primarily due to increased volumes . effective april 1 , 2020 , and consistent with the way management will operate and view the business , the current healthcare products and healthcare specialty services segments will be combined and reported as one segment , simply called healthcare . going forward we will operate and report in three business segments : healthcare , life sciences and applied sterilization technologies . corporate will continue to be presented separately and contain the costs that are associated with being a publicly traded company and certain other corporate costs . liquidity and capital resources the following table summarizes significant components of our cash flows for the years ended march 31 , 2020 and 2019 : replace_table_token_11_th story_separator_special_tag style= `` font-family : inherit ; font-size:10pt ; `` > in fiscal 2019 . the increase in free cash flow is primarily due to the improvement in cash from operations . our debt-to-total capital ratio was 25.3 % at march 31 , 2020 and 27.1 % at march 31 , 2019 . cash requirements . we intend to use our existing cash and cash equivalent balances and cash generated from operations to fund capital expenditures and meet our other liquidity needs . our capital requirements depend on many uncertain factors , including our rate of sales growth , our customers ' acceptance of our products and services , the costs of obtaining adequate manufacturing capacities , the timing and extent of our research and development projects , changes in our operating expenses and other factors . to the extent that existing and anticipated sources of cash are not sufficient to fund our future activities , we may need to raise additional funds through additional borrowings or the sale of equity securities . there can be no assurance that our financing arrangements will provide us with sufficient funds or that we will be able to obtain any additional funds on terms favorable to us or at all . 31 sources of credit . our sources of credit as of march 31 , 2020 are summarized in the following table : replace_table_token_12_th ( 1 ) at march 31 , 2020 , there was $ 6.8 million of letters of credit outstanding under the credit agreement . our sources of funding from credit as of march 31 , 2020 are summarized below : on march 23 , 2018 , steris uk and certain of its subsidiaries entered into a credit agreement

net cash provided by operating activities – the net cash provided by our operating activities was $ 590.6 million for the year ended march 31 , 2020 compared to $ 539.5 million for the year ended march 31 , 2019 . the following discussion summarizes the significant changes in our operating cash flows for the years ended march 31 , 2020 and 2019 : net cash provided by operating activities increased in fiscal 2020 by 9.5 % , as compared to fiscal 2019 , primarily due to higher net income attainment in the fiscal 2020 period , which was partially offset by higher cash requirements to fund operating assets and liabilities . net cash used in investing activities – the net cash used in our investing activities was $ 319.7 million for the year ended march 31 , 2020 , compared to $ 213.2 million for the year ended march 31 , 2019 . the following discussion summarizes the significant changes in our investing cash flows for the years ended march 31 , 2020 and 2019 : purchases of property , plant , equipment , and intangibles , net – capital expenditures totaled $ 214.5 million and $ 189.7 million for fiscal 2020 and 2019 , respectively . the fiscal 2020 increase was primarily due to our previously announced expansion projects in the applied sterilization technologies and healthcare specialty services segments . proceeds from the sale of property , plant , equipment and intangibles – during fiscal 2020 and 2019 we received $ 4.2 million and $ 5.6 million respectively , for proceeds from the sale of property , plant , equipment and intangibles . the majority of the fiscal 2020 and fiscal 2019 proceeds were related to the sale of healthcare products facilities located in the u.k. proceeds from the sale of business – during fiscal 2020 and 2019 we received $ 0.4 million and $ 2.5 million , respectively , for proceeds from the sale of certain non-core businesses .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash provided by operating activities – the net cash provided by our operating activities was $ 590.6 million for the year ended march 31 , 2020 compared to $ 539.5 million for the year ended march 31 , 2019 . the following discussion summarizes the significant changes in our operating cash flows for the years ended march 31 , 2020 and 2019 : net cash provided by operating activities increased in fiscal 2020 by 9.5 % , as compared to fiscal 2019 , primarily due to higher net income attainment in the fiscal 2020 period , which was partially offset by higher cash requirements to fund operating assets and liabilities . net cash used in investing activities – the net cash used in our investing activities was $ 319.7 million for the year ended march 31 , 2020 , compared to $ 213.2 million for the year ended march 31 , 2019 . the following discussion summarizes the significant changes in our investing cash flows for the years ended march 31 , 2020 and 2019 : purchases of property , plant , equipment , and intangibles , net – capital expenditures totaled $ 214.5 million and $ 189.7 million for fiscal 2020 and 2019 , respectively . the fiscal 2020 increase was primarily due to our previously announced expansion projects in the applied sterilization technologies and healthcare specialty services segments . proceeds from the sale of property , plant , equipment and intangibles – during fiscal 2020 and 2019 we received $ 4.2 million and $ 5.6 million respectively , for proceeds from the sale of property , plant , equipment and intangibles . the majority of the fiscal 2020 and fiscal 2019 proceeds were related to the sale of healthcare products facilities located in the u.k. proceeds from the sale of business – during fiscal 2020 and 2019 we received $ 0.4 million and $ 2.5 million , respectively , for proceeds from the sale of certain non-core businesses .
```    
 Suspicious Activity Report : when we discuss revenues , we may , at times , refer to revenues summarized differently than the regulation s-x requirements . the terminology , definitions , and applications of terms that we use to describe revenues may be different from terms used by other companies . we use the following terms to describe revenues : revenues – our revenues are presented net of sales returns and allowances . product revenues – we define product revenues as revenues generated from sales of consumable and capital equipment products . service revenues – we define service revenues as revenues generated from parts and labor associated with the maintenance , repair , and installation of our capital equipment . service revenues also include hospital sterilization services , instrument and scope repairs , and linen management as well as revenues generated from contract sterilization and laboratory services offered through our applied sterilization technologies segment . capital equipment revenues – we define capital equipment revenues as revenues generated from sales of capital equipment , which includes steam sterilizers , low temperature liquid chemical sterilant processing systems , including system 1 and 1e , washing systems , vhp ® technology , water stills , and pure steam generators ; surgical lights and tables ; and integrated or . consumable revenues – we define consumable revenues as revenues generated from sales of the consumable family of products , which includes system 1 and 1e consumables , v-pro consumables , gastrointestinal endoscopy accessories , sterility assurance products , skin care products , cleaning consumables , barrier product solutions and surgical instruments . recurring revenues – we define recurring revenues as revenues generated from sales of consumable products and service revenues . general overview and executive summary steris plc is a leading provider of infection prevention and other procedural products and services . our mission is to help our customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe . we offer our customers a unique mix of innovative consumable products , such as detergents , gastrointestinal ( `` gi `` ) endoscopy accessories , barrier product solutions , and other products and services , including : equipment installation and maintenance , microbial reduction of medical devices , instrument and scope repair solutions , laboratory testing services , on-site and off-site reprocessing , and capital equipment products , such as sterilizers and surgical tables , and connectivity solutions such as operating room ( “ or ” ) integration . on march 28 , 2019 , steris plc , a public limited company organized under the laws of england and wales ( “ steris uk ” ) , completed a redomiciliation from the united kingdom to ireland ( the “ redomiciliation ” ) . the redomiciliation was achieved through the insertion of a new irish public limited holding company ( “ steris ireland ” ) on top of steris uk pursuant to a court-approved scheme of arrangement under english law ( the “ scheme ” ) . following the scheme effectiveness , steris uk was re-registered as a private limited company with the name steris limited , and steris emerald ie limited , a company established in ireland and a wholly-owned direct subsidiary of steris ireland , was interposed as the direct parent company of steris uk . we operate and report in four reportable business segments : healthcare products , healthcare specialty services , life sciences , and applied sterilization technologies . we describe our business segments in note 11 to our consolidated financial statements , titled `` business segment information . `` the bulk of our revenues are derived from the healthcare , medical device and pharmaceutical industries . much of the growth in these industries is driven by the aging of the population throughout the world , as an increasing number of individuals are entering their prime healthcare consumption years , and is dependent upon advancement in healthcare delivery , acceptance of new technologies , government policies , and general economic conditions . the pharmaceutical industry has been impacted by increased regulatory scrutiny of cleaning and validation processes , mandating that manufacturers improve their processes . within healthcare , there is increased concern regarding the level of hospital acquired infections around the world ; increased demand for medical procedures , including preventive screenings such as endoscopies and colonoscopies ; and a desire by our customers to operate more efficiently , all which are driving increased demand for many of our products and services . the covid-19 pandemic is resulting in the deferral of certain elective medical procedures , which is negatively impacting the demand for some of our products and services . we completed several tuck in acquisitions and asset purchases in fiscal 2020 and 2019 that expanded our product and service offerings to our customers . 23 during fiscal 2020 , we sold the operations of our healthcare specialty services business that were located in china with annual revenues of approximately $ 5.0 million . we continue to invest in manufacturing in-sourcing projects and lean process improvements for the purpose of improving quality , cost and delivery of our products to our customers . u.s. tax reform . on december 22 , 2017 , the u.s. government enacted comprehensive tax legislation commonly referred to as the tax cuts and jobs act ( the “ tcja ” ) . story_separator_special_tag ( 5 ) covid-19 incremental costs includes the additional costs attributable to covid-19 such as enhanced cleaning protocols , personal protective equipment for our employees , event cancellation fees , and payroll costs associated with our response to covid-19 , net of any government subsidies available . healthcare products revenues increased 6.3 % in fiscal 2020 , as compared to fiscal 2019 , reflecting growth in consumable , service and capital equipment revenues of 9.5 % , 6.1 % and 4.2 % , respectively . the increase reflects organic growth , which was partially offset by unfavorable fluctuations in currencies . at march 31 , 2020 , the healthcare products segment 's backlog amounted to $ 170.1 million , increasing $ 15.6 million , or 10.1 % , as compared to the backlog of $ 154.5 million at march 31 , 2019. healthcare specialty services revenues increased 10.5 % in fiscal 2020 , as compared to fiscal 2019. the increase reflects organic growth , which was partially offset by the divestiture of our healthcare specialty services business in china and unfavorable fluctuations in currencies . life sciences revenues increased 10.1 % in fiscal 2020 , as compared to fiscal 2019 , reflecting growth in consumable , capital equipment and service revenues of 14.9 % , 9.8 % and 3.7 % , respectively . the increase reflects organic growth and favorable pricing , which were partially offset by unfavorable fluctuations in currencies . life sciences backlog at march 31 , 2020 amounted to $ 72.4 million , increasing $ 11.7 million , or 19.3 % , as compared to backlog of $ 60.7 million at march 31 , 2019. applied sterilization technologies revenues increased 13.0 % in fiscal 2020 , as compared to fiscal 2019. the increase reflects organic growth , which was primarily attributable to increased demand from medical device customers , which was partially offset by unfavorable fluctuations in currencies . 29 the healthcare products segment 's operating income increased $ 32.7 million to $ 356.4 million in fiscal year 2020 , as compared to $ 323.7 million in fiscal year 2019. the segment 's operating margins were 25.0 % for fiscal year 2020 and 24.2 % for fiscal year 2019. the increases in the fiscal 2020 period were primarily due to increased volumes and favorable product mix . the healthcare specialty services segment 's operating income was flat at $ 64.2 million in fiscal years 2020 and 2019. the segment 's operating margins were 11.4 % for fiscal year 2020 and 12.6 % for fiscal year 2019. the fiscal 2020 operating margin benefited from increased volumes , which were more than offset by investments being made to add capacity in anticipation of continuing demand . the life sciences business segment 's operating income increased $ 12.0 million to $ 144.1 million in fiscal year 2020 , as compared to $ 132.1 million in fiscal year 2019 , primarily due to increased volumes . the segment 's operating margins were 34.6 % for fiscal year 2020 and 34.9 % for fiscal year 2019. the decline in the fiscal 2020 operating margin was primarily due to unfavorable product mix . the applied sterilization technologies segment 's operating income increased $ 49.1 million to $ 270.9 million in fiscal year 2020 , as compared to $ 221.8 million in fiscal year 2019. the applied sterilization technologies segment 's operating margins were 43.2 % for fiscal year 2020 and 40.0 % for fiscal year 2019. the increases in the fiscal 2020 period were primarily due to increased volumes . effective april 1 , 2020 , and consistent with the way management will operate and view the business , the current healthcare products and healthcare specialty services segments will be combined and reported as one segment , simply called healthcare . going forward we will operate and report in three business segments : healthcare , life sciences and applied sterilization technologies . corporate will continue to be presented separately and contain the costs that are associated with being a publicly traded company and certain other corporate costs . liquidity and capital resources the following table summarizes significant components of our cash flows for the years ended march 31 , 2020 and 2019 : replace_table_token_11_th story_separator_special_tag style= `` font-family : inherit ; font-size:10pt ; `` > in fiscal 2019 . the increase in free cash flow is primarily due to the improvement in cash from operations . our debt-to-total capital ratio was 25.3 % at march 31 , 2020 and 27.1 % at march 31 , 2019 . cash requirements . we intend to use our existing cash and cash equivalent balances and cash generated from operations to fund capital expenditures and meet our other liquidity needs . our capital requirements depend on many uncertain factors , including our rate of sales growth , our customers ' acceptance of our products and services , the costs of obtaining adequate manufacturing capacities , the timing and extent of our research and development projects , changes in our operating expenses and other factors . to the extent that existing and anticipated sources of cash are not sufficient to fund our future activities , we may need to raise additional funds through additional borrowings or the sale of equity securities . there can be no assurance that our financing arrangements will provide us with sufficient funds or that we will be able to obtain any additional funds on terms favorable to us or at all . 31 sources of credit . our sources of credit as of march 31 , 2020 are summarized in the following table : replace_table_token_12_th ( 1 ) at march 31 , 2020 , there was $ 6.8 million of letters of credit outstanding under the credit agreement . our sources of funding from credit as of march 31 , 2020 are summarized below : on march 23 , 2018 , steris uk and certain of its subsidiaries entered into a credit agreement

